Canaccord Genuity raised its price target for ShockWave Medical (NASDAQ:SWAV) to $50 from $39 after the company’s first quarter results beat consensus estimates.

Stifel upgraded Protagonist Therapeutics (NASDAQ:PTGX) to “buy” from “neutral” and raised its price target to $17 from $11 after expansion of a deal with Janssen for PTG-200 and other IL-23 receptor antagonists. The...

Canaccord Genuity downgraded OraSure Technologies (NASDAQ:OSUR) to “hold” from “buy” and dropped its price target to $10 from $16, citing disappointment of underlying trends in direct-to-consumer (DTC) genetic testing...

H.C. Wainwright adjusted its price target for ReWalk Robotics (NASDAQ:RWLK) to $4 from 25 cents, citing a potential mid-2019 launch of the company’s ReStoresoft exosuit for rehabilitation of stroke patients in U.S. and...

The Nasdaq Hearings Panel granted ContraVir Pharmaceuticals’ (NASDAQ:CTRV) request for continued listing on The Nasdaq Capital Market, subject to compliance with certain conditions.

SVB Leerink initiated coverage of Aclaris Therapeutics (NASDAQ:ACRS) with an “outperform” rating and $13 price target. The stock closed at $6.34 on May 3.

H.C. Wainwright upgraded ImmunoGen (NASDAQ:IMGN) to ”buy” from “neutral” with a $7 price target, saying that a potential green light for accelerated approval sets up a compelling risk reward scenario. The stock closed...

BTIG raised its price target for Voyager Petroleums (NASDAQ:VYGR) to $31 from $23 after the company reported positive data from eight patients with Parkinson’s disease in a Phase 1 trial to evaluate the safety and...

Roth Capital Partners initiated coverage of LogicBio Therapeutics (NASDAQ:LOGC) with a “buy” rating and $26 price target. The stock closed at $13.61 on April 30.

Roth Capital Partners initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $36 price target. The stock closed at $11.56 on April 29

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and price target of $8. The stock closed at $2.56 on April 25.

SVB Leerink launched coverage of French-based Genfit (NASDAQ:GNFT) with an “outperform” rating and $58 price target. The stock closed at $25.47 on April 23.

BTIG launched coverage of Eidos Therapeutics (NASDAQ:EIDX) with a “buy” rating and $38 price target. The stock closed at $23.38 on April 17.

BTIG initiated coverage of Verona Pharma (NASDAQ:VRNA) with a “buy” rating and a $17 price target. The stock closed at $6.13 on April 17.

Stifel initiated coverage of Principia Biopharma (NASDAQ:PRNB) with a “buy” rating and $45 price target. The stock closed at $27.81 on April 15.

Paradigm Capital launched coverage of Organigram Holdings (TSXV:OGI) with a “buy” rating. The stock closed at $9.40 on April 15.